From the Departments of Anaesthesiology.
Obstetrics and Gynecologic Surgery.
Anesth Analg. 2023 Mar 1;136(3):540-550. doi: 10.1213/ANE.0000000000006244. Epub 2022 Oct 24.
To counteract the vasoplegia induced by spinal anesthesia (SA) and maintain blood pressure (BP) during cesarean delivery, phenylephrine is currently recommended, but norepinephrine might offer superior preservation of cardiac output. We aimed to compare the hemodynamic effects of phenylephrine and norepinephrine administered by manually adjusted continuous infusion during elective cesarean delivery.
In this pragmatic, parallel-group, double-blind randomized controlled trial, 124 parturients scheduled for elective cesarean delivery under SA in a tertiary maternity in France, between February 2019 and December 2020, were randomized to receive norepinephrine at a starting rate of 0.05 μg·kg -1 ·min -1 (n = 62) or phenylephrine at a starting rate of 0.5 μg·kg -1 ·min -1 (n = 62). In both groups, the vasopressor infusion rate was then manually adjusted to maintain maternal systolic BP above 90% of the baseline value. The primary outcome, the change in cardiac index (CI) measured by thoracic bioreactance from SA to umbilical cord clamping, was analyzed through repeated measures analysis of variance and post hoc t tests. Secondary outcomes included maternal BP and neonatal outcomes.
In the norepinephrine group, cardiac index was maintained between 90% and 100% of baseline from SA to umbilical cord clamping, whereas it was maintained at significantly lower values (81%-88%) in the phenylephrine group ( P = .001). The percentage of elapsed time with a mean maternal BP <65 mm Hg and with systolic BP <80% of the baseline value was higher in the phenylephrine group: 2.9% (7.3) vs 0.5% (1.8) (absolute risk difference [ARD], -2.4%; 95% confidence interval, -4.4 to -0.5; P = .012) and 8.5% (16.6) vs 2.3% (5.2) (ARD, -6.2%; 95% confidence interval, -10.6 to -1.8; P = .006). Excluding parturients with gestational diabetes, severe neonatal hypoglycemia was more common in the phenylephrine group at 19.6% (9/46) vs 4.1% (2/49) ( P = .02). The other neonatal outcomes did not differ significantly between the groups.
When administered by manually adjusted infusion during SA for cesarean delivery, norepinephrine was associated with a higher CI; both infusions were effective for maintaining BP.
为了对抗脊髓麻醉(SA)引起的血管扩张,并在剖宫产期间维持血压(BP),目前推荐使用去氧肾上腺素,但去甲肾上腺素可能更有利于维持心输出量。我们旨在比较在择期剖宫产期间通过手动调整连续输注给予去氧肾上腺素和去甲肾上腺素的血流动力学效应。
在这项实用的、平行组、双盲随机对照试验中,法国一家三级妇产医院于 2019 年 2 月至 2020 年 12 月期间,对 124 例接受 SA 择期剖宫产的产妇进行了随机分组,分别接受去甲肾上腺素起始剂量 0.05 μg·kg -1 ·min -1 (n = 62)或去氧肾上腺素起始剂量 0.5 μg·kg -1 ·min -1 (n = 62)。在两组中,均通过手动调整血管加压素输注率来维持产妇的收缩压高于基线值的 90%。通过重复测量方差分析和事后 t 检验分析主要结局,即从 SA 到脐带夹闭时通过胸部生物电阻抗测量的心脏指数(CI)的变化。次要结局包括产妇血压和新生儿结局。
在去甲肾上腺素组,从 SA 到脐带夹闭时心脏指数维持在基线值的 90%至 100%之间,而在去氧肾上腺素组则维持在明显较低的值(81%-88%)( P =.001)。在去氧肾上腺素组,平均产妇血压<65mmHg 和收缩压<80%基线值的时间百分比更高:2.9%(7.3)比 0.5%(1.8)(绝对风险差异[ARD],-2.4%;95%置信区间,-4.4 至-0.5; P =.012)和 8.5%(16.6)比 2.3%(5.2)(ARD,-6.2%;95%置信区间,-10.6 至-1.8; P =.006)。排除患有妊娠期糖尿病的产妇后,去氧肾上腺素组严重新生儿低血糖的发生率为 19.6%(9/46),而去甲肾上腺素组为 4.1%(2/49)( P =.02)。两组新生儿其他结局无显著差异。
在 SA 用于剖宫产期间通过手动调整输注时,去甲肾上腺素与更高的 CI 相关;两种输注均有效维持血压。